Skip to main content
. 2016 Jan 25;34(10):1112–1121. doi: 10.1200/JCO.2015.64.5929

Fig 3.

Fig 3.

Rapid eradication of diffuse large–B-cell lymphoma after allogeneic CAR19 T-cell infusion. (A) Magnetic resonance images show rapid complete elimination of lymphoma masses (arrows). Images are from before treatment, 15 days after anti-CD19 chimeric antigen receptor (CAR19) T-cell infusion, and 99 days after CAR19 T-cell infusion. The remission continued over 6 months after infusion. (B) Positron emission tomography scan shows metabolically active lymphoma before CAR19 T-cell infusion (arrows). Thirty-five days after the CAR19 T-cell infusion, the scan showed no evidence of lymphoma. (C) The event-free survival of all 20 patients treated on the study is shown. Events were defined as progression of malignancy, receipt of any antimalignancy therapy after CAR19 T-cell infusion, or death from any cause. (D) The overall survival of all 20 patients treated on the study is shown. For (C) and (D), survival fractions were calculated by Kaplan-Meier method, and gold lines indicate censored patients.